BRPI1013227A2 - pró-fármacos transportadores de interferon alfa - Google Patents

pró-fármacos transportadores de interferon alfa

Info

Publication number
BRPI1013227A2
BRPI1013227A2 BRPI1013227A BRPI1013227A BRPI1013227A2 BR PI1013227 A2 BRPI1013227 A2 BR PI1013227A2 BR PI1013227 A BRPI1013227 A BR PI1013227A BR PI1013227 A BRPI1013227 A BR PI1013227A BR PI1013227 A2 BRPI1013227 A2 BR PI1013227A2
Authority
BR
Brazil
Prior art keywords
transporter
prodrugs
interferon alpha
interferon
alpha
Prior art date
Application number
BRPI1013227A
Other languages
English (en)
Inventor
Harald Rau
Silvia Kaden-Vagt
Original Assignee
Ascendis Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma As filed Critical Ascendis Pharma As
Publication of BRPI1013227A2 publication Critical patent/BRPI1013227A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BRPI1013227A 2009-03-05 2010-03-04 pró-fármacos transportadores de interferon alfa BRPI1013227A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09154449 2009-03-05
EP09180477 2009-12-22
PCT/EP2010/052745 WO2010100220A1 (en) 2009-03-05 2010-03-04 Interferon alpha carrier prodrugs

Publications (1)

Publication Number Publication Date
BRPI1013227A2 true BRPI1013227A2 (pt) 2016-03-29

Family

ID=42041523

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013227A BRPI1013227A2 (pt) 2009-03-05 2010-03-04 pró-fármacos transportadores de interferon alfa

Country Status (10)

Country Link
US (1) US20120058084A1 (pt)
EP (1) EP2403537A1 (pt)
JP (1) JP2012519666A (pt)
CN (1) CN102413843A (pt)
AU (1) AU2010220324A1 (pt)
BR (1) BRPI1013227A2 (pt)
CA (1) CA2753001A1 (pt)
MX (1) MX2011008963A (pt)
RU (1) RU2011140219A (pt)
WO (1) WO2010100220A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3543256A1 (en) * 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
CA2769340C (en) 2009-07-31 2018-09-11 Harald Rau Prodrugs comprising an insulin linker conjugate
SG178195A1 (en) 2009-07-31 2012-03-29 Sanofi Aventis Deutschland Long acting insulin composition
WO2011042453A1 (en) 2009-10-06 2011-04-14 Ascendis Pharma As Subcutaneous paliperidone composition
CA2776723C (en) 2009-10-29 2018-09-25 Ascendis Pharma As Sterilization of biodegradable hydrogels
CN102711733A (zh) 2009-12-15 2012-10-03 阿森迪斯药物股份有限公司 瞬时连接于聚合物载体的干生长激素组合物
EP2525829A1 (en) 2010-01-22 2012-11-28 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
EP2525831B1 (en) 2010-01-22 2019-05-15 Ascendis Pharma A/S Carrier-linked carbamate prodrug linkers
WO2011089216A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
PL2616101T3 (pl) 2010-09-14 2015-01-30 Hoffmann La Roche Sposób oczyszczania pegylowanej erytropoetyny
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
FR2975301B1 (fr) 2011-05-20 2013-05-24 Flamel Tech Sa Composition comprenant un interferon alpha
DK2583680T1 (da) 2011-10-21 2015-01-19 Abbvie Inc Mono (PSI-7977) eller kombinationsbehandling af DAA til anvendelse ved behandling af HCV
CN104383541A (zh) 2011-10-21 2015-03-04 艾伯维公司 用于治疗hcv的包含至少两种直接抗病毒剂和利巴韦林但无干扰素的方法
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8383093B1 (en) 2011-11-01 2013-02-26 Serina Therapeutics, Inc. Subcutaneous delivery of poly(oxazoline) conjugates
MX363462B (es) * 2012-10-11 2019-03-25 Ascendis Pharma As Diagnostico, prevencion y tratamiento de enfermedades de la articulacion.
EP3220892B1 (en) 2014-11-21 2021-10-13 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms
CA3022119A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
KR20210153092A (ko) 2019-04-15 2021-12-16 퀴셀 세라퓨틱스 엘엘씨 암 치료에 사용하기 위한, 마스킹된 유형 i 인터페론(ifna 및 ifnb) 및 종양 항원에 대한 항체를 포함하는 융합 단백질 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3812507A1 (de) 1988-04-15 1989-10-26 Sachsenwerk Ag Schaltfeld fuer eine gekapselte mittelspannungs-schaltanlage
DE19510438A1 (de) 1995-03-22 1996-09-26 Basf Ag Verfahren zur Herstellung von 1,4-Butandiol und Tetrahydrofuran aus Furan
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
CA2312975C (en) 1997-12-17 2012-08-21 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
AU2003256038A1 (en) 2002-08-30 2004-03-19 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
AU2003282624A1 (en) 2002-11-14 2004-06-03 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
JP4698579B2 (ja) * 2003-04-08 2011-06-08 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 可逆的peg化薬物
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
ES2741524T3 (es) 2004-03-23 2020-02-11 Ascendis Pharma Gmbh Profármaco polimérico con un enlazador autoinmolador
EP1625855A1 (en) * 2004-08-13 2006-02-15 Complex Biosystems GmbH Polymeric prodrug with a self-immolative linker
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
EP1679065A1 (en) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker

Also Published As

Publication number Publication date
US20120058084A1 (en) 2012-03-08
JP2012519666A (ja) 2012-08-30
EP2403537A1 (en) 2012-01-11
WO2010100220A1 (en) 2010-09-10
CN102413843A (zh) 2012-04-11
AU2010220324A1 (en) 2011-09-01
RU2011140219A (ru) 2013-04-10
MX2011008963A (es) 2012-02-01
CA2753001A1 (en) 2010-09-10

Similar Documents

Publication Publication Date Title
NL301211I1 (nl) Olipudase alfa
BRPI1013227A2 (pt) pró-fármacos transportadores de interferon alfa
NO2020033I1 (no) andeksanet alfa
NL301210I2 (nl) Avalglucosidase alfa
SMT201600351B (it) Composti antivirali
FIC20230032I1 (fi) Pegunigalsidaasi alfa
BR112012001777A2 (pt) serigrafia
BRPI1010661A2 (pt) peptídeo
FR2947857B1 (fr) Agencement de deshuileur
DE102009055987A8 (de) Spinell-Optokeramiken
BR112012001722A2 (pt) projetor de led
BRPI0922716A2 (pt) purificação de polipeptídeo
NL300948I2 (nl) velmanase alfa
DK2499421T3 (da) Højeffektive lysdioder
DK3696491T3 (da) Leddelt målestok
NO20091539L (no) Fôringsflate
DE102009055010A8 (de) Dachanordnung
ES1071536Y (es) Tirafondo de cabeza avellanada
FI20096108A (fi) Järjestely
NO20093038A (no) Skip
FI8681U1 (fi) Tarttuja
CR10574S (es) Bloques alfa
DOS2009000074S (es) Molduras
CN301122338S (zh) 数字直接控制器(mktx6rm)
CN301117116S (zh) 数字直接控制器(mktx6r)

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 47/60 (2017.01)